Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research Grade Epratuzumab | Login | Research Grade Epratuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Bectumomab | Login | Research Grade Bectumomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Anti-Human CD22 Antibody (Immurait-Ll2Mab) | Login | Research Grade Anti-Human CD22 Antibody (Immurait-Ll2Mab) | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Pinatuzumab | Login | Research Grade Pinatuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Lumiliximab | Login | Research Grade Lumiliximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Gomiliximab | Login | Research Grade Gomiliximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Inolimomab | Login | Research Grade Inolimomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Begelomab | Login | Research Grade Begelomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Varlilumab | Login | Research Grade Varlilumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Iratumumab | Login | Research Grade Iratumumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Lintuzumab | Login | Research Grade Lintuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Vadastuximab | Login | Research Grade Vadastuximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Lilotomab | Login | Research Grade Lilotomab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Naratuximab | Login | Research Grade Naratuximab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Otlertuzumab | Login | Research Grade Otlertuzumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Mezagitamab | Login | Research Grade Mezagitamab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Felzartamab | Login | Research Grade Felzartamab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Modakafusp alfa | Login | Research Grade Modakafusp alfa | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Iscalimab | Login | Research Grade Iscalimab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Bleselumab | Login | Research Grade Bleselumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Selicrelumab | Login | Research Grade Selicrelumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Giloralimab | Login | Research Grade Giloralimab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Lucatumumab | Login | Research Grade Lucatumumab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Mitazalimab | Login | Research Grade Mitazalimab | ||||||||||||||||
|
||||||||||||||||||
| Research Grade Vanalimab | Login | Research Grade Vanalimab | ||||||||||||||||
|
||||||||||||||||||


